DEXFENFLURAMINE

- Everything we could find out about it

Home ] [ Controlled Substances ] [ Stimulants ]

Created May 2019 | Updated Oct 2020

DEXFENFLURAMINE

  • [REDUX]

DEA CODE 1670: Schedule 4

Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. Dexfenfluramine, the dextrorotatory isomer of fenfluramine, is indicated for use in the management of obesity in patients with a body mass index of > or = 30 kg/m2, or > or = 27 kg/m2 in the presence of other risk factors. Unlike fenfluramine, dexfenfluramine is a pure serotonin agonist. Dexfenfluramine increases serotonergic activity by stimulating serotonin (5-hydroxytryptamine; 5-HT) release into brain synapses, inhibiting its reuptake into presynaptic neurons and by directly stimulating postsynaptic serotonin receptors.

Dexfenfluramine reduces blood pressure, percent glycosylated hemoglobin, and concentrations of blood glucose and blood lipids, but these benefits may be indirect. Dexfenfluramine may also be of some value in controlling eating habits in diabetic patients, preventing weight gain after smoking cessation, and treating bulimia, seasonal affective disorder, neuroleptic-induced obesity, and premenstrual syndrome.

Dexfenfluramine's most frequent adverse effects are insomnia, diarrhea, and headache; it has also been associated with primary pulmonary hypertension. The drug should not be combined with other serotonergic agonists because of the risk of serotonin syndrome. The recommended dosage is 15 mg twice daily. Dexfenfluramine is effective in the treatment of obesity in selected patients. Because its efficacy is lost after six months of continuous treatment, it should be viewed primarily as an adjunct to diet and exercise. Dexfenfluramine was approved by the FDA in 1996 and has been widely used for the treatment of obesity. However, Dexfenfluramine was removed from the U.S. market in 1997 following reports of valvular heart disease and pulmonary hypertension.

Dexfenfluramine is a anorectic drug used to aid in weight loss. It is an appetite suppressant that functions by causing the release of the neurochemical serotonin. This is done by disrupting serotonin storage sites in the brain. The released serotonin causes a loss of appetite, and, in many people, also causes a feeling of fullness. This is one of several similar weight-loss supplements that was produced and marketed in the late 1980s and early 1990s. All of these supplements are anorectic, which is derived from Greek and translates as without appetite. Dexfenfluramine was also used to create a similar compound, fenfluramine, which is a combination of dexfenfluramine and levofenfluramine.

Dexfenfluramine was removed from the market by the United States Food and Drug Administration in 1997, after reports surfaced indicating that it caused serious cardiovascular side effects. These included heart valve disease and cardiac fibrosis. Dexfenfluramine was marketed in the United States under the name Redux, by Wyeth-Ayerst Laboratories.

Student Paper from 1998:
Redux is commonly taken by overweight people. The primary task is to lessen the calorie intake related to an increased serotonin level in the brain. This increases level provides the sense of satisfaction which obese people lack. An increase in serotonin ( a hormone in the brain) eventually leads to weight loss. The combination of a decrease in caloric intake along with the excess production of serotonin by redux is what causes some to lose body weight. This redux treatment is associated with a loss of appetite and may slow gastric emptying.

One of the biggest goals Americans today set for themselves is to lose weight. It is a quest which many seek out and never reach. The twentieth century has brought about many changes in the world, but it has also brought about many self image problems. With waif-thin models walking the runway, and anorexic fourteen year olds as our role models it is not a wonder. Many young and older women are feeling threatened to fit this particular image.

Naturally, the lack in self confidence and esteem in these women has motivated doctors to new heights. Women want to be thin, so we will get them there. This is the mentality of many doctors; it is also for some women. Looking good has become such a goal for so many women that it outweighs the methods of getting there.

The non-obese person maintains normal weight without drugs. He/She experiences a sense of fullness which informs them when it is time to stop eating, simply stated- "I have had enough." Studies, similar to one in Metabolism, have shown that these feelings of fullness occur when certain neuro transmitters in the brain, known as serotonin molecules, are released

With the development of fenfluramine, or fen-phen, and dexfenfluramine, more commonly known as Redux, many females have been reaching their aspirations. Many concerns have been raised, however, with the side-effects and risks of these weight loosing pills.

What technology and further medical development holds for us in the future is unknown. Our bodies our very precious things. Weight loss plays an important factor in very few cases. People need to resolve to the "old fashion" ways of loosing weight; such as eating right and exercising regularly. Until the day when people become happy with themselves or find healthier methods of weight loss, we are stuck in this whirlpool of unsafe and hazardous methods.

Dexfenfluramine:

It was for some years in the mid-1990s, approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, the FDA withdrew the approval in 1997

  • A serotonergic anorectic drug
  • It reduces appetite by increasing the amount of extracellular serotonin in the brain
  • Structurally similar to fenfluramine and amphetamine, but lacks any psychologically stimulating effects

  
What happens when you go off weight-loss drugs? - Next-gen anti-obesity drugs like injectable liraglutide, sold as Saxenda, deliver impressive results in the first 12 months. New research looks into what happens to those results once treatment stops.
Tuesday February 20, 2024 - newatlas.com

Adipex-p - PPH has been reported when phentermine was combined with fenfluramine or dexfenfluramine and with ... and to other related stimulant drugs that have been extensively abused. Consider the abuse ...
Thursday February 01, 2024 - empr.com

Ozempic for Weight Loss: This Diabetes Medication Should Not Be Used As a Diet Drug - S ociety seems to have a generational trend cycle when it comes to weight loss and appearance politics. The late ‘90s and early 2000s brought on an obsession with diet pills and ...
Tuesday February 28, 2023 - msn.com

Binge Eating Disorder: Recognition, Diagnosis, and Treatment - the magnitude of dexfenfluramine's effect over placebo was increased. However, it is important to note that binge eating frequency returned to pretreatment levels after the drug was discontinued ...
Sunday February 04, 2024 - medscape.com

10,000 patients have filed ‘gastro’ claims against Ozempic, Mounjaro drug makers - After Weintraub published his findings in 1992, doctors began prescribing the diet drug duo, despite the ... for a more powerful substance called dexfenfluramine. Despite considering ...
Thursday January 25, 2024 - benefitspro.com

Biotech weighs up the options in obesity - However, the fate of two highly publicized weight-reducing drugs has cast a long shadow over the field. The highly publicized withdrawal of Redux (dexfenfluramine) and fenfluramine, which were ...
Tuesday January 01, 2019 - nature.com

Too Good to Be True? Ozempic Lawsuit Moves Forward as Gastrointestinal Issues Surface - After Weintraub published his findings in 1992, doctors began prescribing the diet drug duo, despite the ... for a more powerful substance called dexfenfluramine. Despite considering ...
Sunday January 21, 2024 - law.com

Artesunate Interaction with other Drugs - The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Dexfenfluramine resulting in a loss in efficacy. The serum concentration ...
Monday February 03, 2020 - medindia.net

Consumer group seeks Sibutramine ban - In 1998, the FDA pulled two diet drugs from the market, fenfluramine and dexfenfluramine, because of concern over heart-valve problems. Sibutramine, marketed as Meridia by Abbott Laboratories ...
Thursday December 21, 2023 - medindia.net

Pharmacologic Options for the Treatment of Obesity - Many reports of cardiac valve abnormalities were also blamed on the two drugs. In the summer of 1997, FDA requested a voluntary withdrawal of fenfluramine and dexfenfluramine. [25] The ...
Saturday July 14, 2001 - medscape.com

Sidelining Safety — The FDA's Inadequate Response to the IOM - Drugs for the treatment of common chronic conditions such as diabetes (troglitazone), obesity (dexfenfluramine), and pain (rofecoxib) were approved under expedited programs and later were ...
Wednesday September 05, 2007 - nejm.org

  
Stimulants | Link to this page

Home ] [ Controlled Substances ] [ Sources ]


· Controlled Substances
· Stimulants
· Dexfenfluramine